Literature DB >> 20493735

Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs.

Dominic Hollman1, Susan M Coupey, Amy S Fox, Betsy C Herold.   

Abstract

PURPOSE: The importance of diagnosing trichomoniasis is highlighted by its strong association with HIV acquisition and viral shedding. The low sensitivity of wet preparation and often asymptomatic nature of trichomoniasis results in failure to recognize and treat this sexually transmitted infection. The purpose of this study was to evaluate the feasibility of screening high-risk adolescent females using a new highly sensitive and specific NAAT assay.
METHODS: We enrolled a consecutive, clinical sample of 144 sexually active females, aged 13 through 21. Subjects completed a questionnaire on sexual history and current vaginal symptoms, and provided two self- or physician-collected vaginal swabs and urine. A wet preparation test was performed with one swab and the APTIMA Trichomonas vaginalis (ATV) assay (Gen-Probe, Inc.) was performed with the other and with urine.
RESULTS: Mean age was 18 +/- 1.6 years; 55% Hispanic and 35% black. A three-fold higher prevalence of trichomoniasis (6.3%) was detected by ATV than by wet preparation (2.1%) with 100% concordance between vaginal swab and urine. Prevalence of chlamydia by APTIMA was 11%; no gonorrhea was detected. Subjects with trichomoniasis were more likely than those without to be black (P < 0.01), and to report past gonorrhea (P < 0.01) and past PID (P < 0.001). No vaginal symptom distinguished those with trichomoniasis.
CONCLUSION: Three times as many cases of trichomoniasis were identified with ATV compared to wet preparation and identical results were obtained with vaginal swabs and urine. No symptoms were associated with trichomoniasis. These findings highlight the imperative and feasibility of screening and treating at-risk populations. Copyright 2010 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20493735     DOI: 10.1016/j.jpag.2010.03.004

Source DB:  PubMed          Journal:  J Pediatr Adolesc Gynecol        ISSN: 1083-3188            Impact factor:   1.814


  13 in total

Review 1.  Mycoplasma genitalium and Trichomonas vaginalis: addressing disparities and promoting public health control of two emerging sexually transmitted infections.

Authors:  Faye Korich; Neha G Reddy; Maria Trent
Journal:  Curr Opin Pediatr       Date:  2020-08       Impact factor: 2.856

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay.

Authors:  C C Ginocchio; K Chapin; J S Smith; J Aslanzadeh; J Snook; C S Hill; C A Gaydos
Journal:  J Clin Microbiol       Date:  2012-05-23       Impact factor: 5.948

4.  Prevalence of Trichomonas vaginalis Among Civilian, Noninstitutionalized Male and Female Population Aged 14 to 59 Years: United States, 2013 to 2016.

Authors:  Elaine W Flagg; Elissa Meites; Christi Phillips; John Papp; Elizabeth A Torrone
Journal:  Sex Transm Dis       Date:  2019-10       Impact factor: 2.830

5.  Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance parameters and epidemiological implications.

Authors:  Sarah B Andrea; Kimberle C Chapin
Journal:  J Clin Microbiol       Date:  2011-01-19       Impact factor: 5.948

6.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

7.  Development of PCR assays for detection of Trichomonas vaginalis in urine specimens.

Authors:  Claudiu I Bandea; Kahaliah Joseph; Evan W Secor; Laurie A Jones; Joseph U Igietseme; Robert L Sautter; Margaret R Hammerschlag; Nancy N Fajman; Rebecca G Girardet; Carolyn M Black
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

Review 8.  A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Authors:  Elissa Meites; Charlotte A Gaydos; Marcia M Hobbs; Patricia Kissinger; Paul Nyirjesy; Jane R Schwebke; W Evan Secor; Jack D Sobel; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

9.  Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.

Authors:  Patricia Kissinger; Christina A Muzny; Leandro A Mena; Rebecca A Lillis; Jane R Schwebke; Laura Beauchamps; Stephanie N Taylor; Norine Schmidt; Leann Myers; Peter Augostini; William E Secor; Martina Bradic; Jane M Carlton; David H Martin
Journal:  Lancet Infect Dis       Date:  2018-10-05       Impact factor: 25.071

10.  Prevalence, Clinical Criteria and Sociodemographic Predictors of Trichomonas vaginalis Infection in Suspected Egyptian Women, Using Direct Diagnostic Techniques.

Authors:  Atef Hussein Hussein; Mohamed Hussein Saleh; Ibrahim Maged Nagaty; Khaled A Ghieth; Nagat Ahmed El-Azab
Journal:  Iran J Parasitol       Date:  2015 Jul-Sep       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.